Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06493409 · ClinicalTrials.gov registry record · Phase 1

A Study to Assess the Effect of Voriconazole and Quinidine on the Pharmacokinetics of a Single Dose of Repotrectinib in Healthy Participants

A Phase 1 study of Healthy Volunteers, sponsored by Bristol-Myers Squibb.

Completed
Registry status
Phase 1
Development phase
32
Enrollment target
1
Study location

NCT06493409 is a Phase 1 study of Healthy Volunteers that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 32 participants, below the 482-participant average among 283 other Healthy Volunteers trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06493409, a Phase 1 study of Healthy Volunteers, has completed, sponsored by Bristol-Myers Squibb.

COMPLETED
Registry status
Phase 1
Development phase
32 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to evaluate the effects of coadministration of voriconazole or quinidine on the pharmacokinetics (PK) of repotrectinib in healthy male and female (individual not of childbearing potential \[INOCBP\]) participants.

Conditions Studied

Interventions

  • DRUG Repotrectinib
  • DRUG Voriconazole
  • DRUG Quinidine

Study Locations (1)

Florida

  • Fortrea - Daytona Beach - Daytona Beach

Trial Details

FieldValue
Enrollment Target 32 participants
Start Date 2024-08-26
Est. Completion 2024-12-07
Phase Phase 1

Sponsor

Bristol-Myers Squibb

1,025 total trials

What the Registry Record Tells You About NCT06493409

The ClinicalTrials.gov registry entry for NCT06493409 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 482-participant average among 283 other Healthy Volunteers trials with a reported enrollment target (93% lower). The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Healthy Volunteers appearing as the primary indexed condition, and to 3 interventions - of which Repotrectinib is the first listed.

NCT06493409 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.

Frequently Asked Questions

What is clinical trial NCT06493409 about?

NCT06493409 is a clinical study titled "A Study to Assess the Effect of Voriconazole and Quinidine on the Pharmacokinetics of a Single Dose of Repotrectinib in Healthy Participants". The purpose of this study is to evaluate the effects of coadministration of voriconazole or quinidine on the pharmacokinetics (PK) of repotrectinib in healthy male and female (individual not of childbearing potential \[INOCBP\]) participants.

What is the current status of trial NCT06493409?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2024-08-26. Estimated completion is 2024-12-07.

What conditions does trial NCT06493409 study?

This clinical trial studies the following conditions: Healthy Volunteers.

What interventions are being tested in trial NCT06493409?

The interventions under investigation include: Repotrectinib (DRUG), Voriconazole (DRUG), Quinidine (DRUG).

Who is sponsoring clinical trial NCT06493409?

This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06493409 being conducted?

This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Healthy Volunteers

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.